Michael A. Morgan, PhD, is a project manager and emerging science and technology advisor at the U.S. Food and Drug Administration, where he works in the Office of Regulatory and Emerging Science, Office of the Chief Scientist, Office of the Commissioner. Currently, Dr. Morgan co-leads a team of 50 experts from across FDA developing Elsa, FDA’s first enterprise generative AI chatbot. To date, over 70% of staff have voluntarily used the tool. He also serves as a Commissioner's Office representative to the FDA AI Internal Council, FDA's final decision-making body for internal AI policies and guidelines.

‍

Previously, Dr. Morgan served on detail at the Department of Health and Human Services (HHS), where he co-led the evaluation and analysis of over 500 HHS AI use cases and provided technical and business expertise to guide HHS leadership in acquiring cutting-edge AI solutions, platforms, and environments. Before his HHS detail, Dr. Morgan developed a novel AI horizon scanning tool at FDA to identify emerging health-related science and technologies and forecast their potential regulatory impact. The tool was adopted by the Office of Personnel Management.

‍

Dr. Morgan completed a postdoctoral fellowship at the U.S. Naval Research Laboratory and received his graduate degree from the University of Maryland, College Park, and his undergraduate degree from Syracuse University, both in biochemistry.